Benitec last week experienced another setback in its attempts to maintain its core US patent after the US Patent and Trademark Office opted not to accept the company's most recent response to the ongoing re-examination of the intellectual property.

According to Benitec, the patent office decided not to enter into the re-examination proceedings the company's proposed amendments to the patent, as well as related arguments and evidence. The expressed RNAi shop said it may appeal the decision, which it said the agency made based purely on procedural grounds.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.